Development of anti-and pro-apoptotic drugs via regulation of VDAC, a mitochondrial outermembrane protein
Development of anti-and pro-apoptotic drugs via regulation of VDAC, a mitochondrial outermembrane protein
批准号:
14370058
负责人:
SHIMIZU Shigeomi
金额:
$8.26万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Voltage-dependent anion channel (VDAC) is a channel protein existed on mitochondrial outer membrane. VDAC plays a crucial role for cell living as well as cell death, via regulating mitochondrial membrane permeability. Therefore, in order to develop the anti-and pro-apoptotic drugs, I planned two studies ; (1)Identification of VDAC-regulating drugs, and (2)Development of drugs that inhibit VDAC-hexokinase interaction, which is crucial for cancer cell viability through regulation of glycolysis.(1)Identification of VDAC-regulating drugs-(A)Previously, I found that anti-apoptotic protein Bcl-2/Bcl-xL regulated VDAC through direct interaction. I searched the binding site and found that N-terminal 20 amino acids (called BH4 region) were crucial. To produce cell-permeable form, 9 amino acids derived from HIV-Tat protein were fused. This Tat-BH4 peptide closed VDAC channel in isolated mitochondria, and prevented various forms of apoptosis in cultured cells. Furthermore, when this peptides were administrated into mice, radiation-induced colitis, ischemic heart disease, and fulminant hepatitis were dramatically improved. (B)To identify other VDAC-regulating agents, I screened the various antibiotics and small molecules using isolated mitochondria. From antibiotics library, I found several molecules which cancelled anti-apoptotic Bcl-2 function via regulating VDAC channel, from small molecules screening, I found anti-apoptotic reagent. Now, I tested the effect of these molecules in vivo.(2)Development of drugs that inhibit VDAC-hexokinase interaction-Although I tried several screening to identify the drugs that inhibit VDAC-hexokinase interaction. But, I could not identified yet.
期刊论文(43)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
R.Sugioka, et al.: "BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo"Oncogene. 22. 8432-8440 (2003)
R.Sugioka 等人:“来自 Bcl-xL 的 BH4 结构域肽在体内发挥抗凋亡活性”癌基因。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hosoda, H. et al.: "Structural divergence of human ghrelin ; identification of multiple ghrelin-derived molecules produced by post-translational processing."J.Biol.Chem.. 278. 64-70 (2003)
Hosoda, H. 等人:“人生长素释放肽的结构分歧;翻译后加工产生的多种生长素释放肽衍生分子的鉴定。”J.Biol.Chem.. 278. 64-70 (2003)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
A.Konishi, et al.: "Involvement of histone H1.2 in apoptosis induced by DNA double-strand breaks"Cell. 114. 673-688 (2003)
A.Konishi 等人:“组蛋白 H1.2 参与 DNA 双链断裂诱导的细胞凋亡”细胞。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Y.Akao, et al.: "Mitochondrial permeability transition mediates apoptosis induced by N-methyl 【○!R】 salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-amiaoindan"J. Neurochem. 82. 913-923 (2002)
Y.Akao 等人:“线粒体通透性转变介导由 N-甲基 [○!R] Salsolinol(一种内源性神经毒素)诱导的细胞凋亡,并被 Bcl-2 和雷沙吉兰、N-propargyl-1(R)-amiaoindan 抑制“J. Neurochem. 82. 913-923 (2002)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Y.Shinohara, et al.: "Permeability transition-independent release of mitochondrial cytochrome cinduced by valinomycin"Eur.J.Biochem.. 269. 5224-5230 (2002)
Y.Shinohara等人:“缬氨霉素诱导的线粒体细胞色素c的渗透性转变独立释放”Eur.J.Biochem.269.5224-5230(2002)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 15 条
Development of small compounds that induce alternative autophagy
-
批准号:16K15230
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2016
-
负责人:SHIMIZU Shigeomi
-
依托单位:
Development of autophagy visualization tools and analyses of physiological roles of autophagy
-
批准号:25670139
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.5万
-
财政年份:2013
-
负责人:SHIMIZU Shigeomi
-
依托单位:
Structural analysis of mitochondrial apoptotic pore
-
批准号:23657084
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.5万
-
财政年份:2011
-
负责人:SHIMIZU Shigeomi
-
依托单位:
Studies of alternative macroautophagy and its application for "Autophagic Diseases"
-
批准号:22229002
-
项目类别:Grant-in-Aid for Scientific Research (S)
-
资助金额:$139.11万
-
财政年份:2010
-
负责人:SHIMIZU Shigeomi
-
依托单位:
Analysis of biological role and molecular mechanisms of autophagic cell death
-
批准号:17390094
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.64万
-
财政年份:2005
-
负责人:SHIMIZU Shigeomi
-
依托单位:
Identification of novel cytochrome c releasing factor and analysis of its molecular function on apoptosis
-
批准号:12680695
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.56万
-
财政年份:2000
-
负责人:SHIMIZU Shigeomi
-
依托单位:
Novel cancer gene therapy using apoptosis-related gene
-
批准号:09671304
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:1997
-
负责人:SHIMIZU Shigeomi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
DJ-1与Calnexin互作调控线粒体—内质网联络区参与帕金森病病理机制的研究
-
批准号:82371414
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:黄沛
-
依托单位:
MitoNEET通过调控线粒体形态和功能减轻肾脏缺血再灌注损伤的作用及机制研究
-
批准号:32100537
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:齐元博
-
依托单位:
线粒体炫和活性氧信号调控细胞能量代谢平衡的机制研究
-
批准号:92157105
-
项目类别:重大研究计划
-
资助金额:54.0万元
-
批准年份:2021
-
负责人:王显花
-
依托单位:
基于超分辨活细胞成像的MDVs形成过程及分子机制的研究
-
批准号:32000480
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:郭玉婷
-
依托单位:
线粒体互作网络调控线粒体稳态并参与乳腺癌发生发展的机制研究
-
批准号:92054108
-
项目类别:重大研究计划
-
资助金额:87.0万元
-
批准年份:2020
-
负责人:卫涛涛
-
依托单位:
脂滴与线粒体的互作在巨噬细胞和动脉粥样硬化中的作用及机制研究
-
批准号:32000482
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:魏园园
-
依托单位:
线虫线粒体组织特异性分离及其蛋白组学分析
-
批准号:31900498
-
项目类别:青年科学基金项目
-
资助金额:26.0万元
-
批准年份:2019
-
负责人:任学聪
-
依托单位:
重编程早期线粒体通透性转换孔开放对PHF8的调控及机制
-
批准号:31970709
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:应仲富
-
依托单位:
PET117蛋白与细胞核-线粒体基因表达协调
-
批准号:31970654
-
项目类别:面上项目
-
资助金额:52.0万元
-
批准年份:2019
-
负责人:丁健
-
依托单位:
线粒体beta-桶膜蛋白调控生物大分子跨膜转运的分子机制
-
批准号:31972886
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:邱健
-
依托单位: